- Citius Pharmaceuticals Inc. announced and closed a **registered direct offering** on **October 21, 2025**, generating approximately **$6.0 million** in gross proceeds.  **[1506251_0001213900-25-100847_ea026190901ex99-1_citius.htm:0]** **[1506251_0001213900-25-100847_ea026190901ex99-2_citius.htm:0]** 
- The offering included the sale of **3,973,510 shares** of common stock (or pre-funded warrants) and accompanying common warrants, at a purchase price of **$1.51 per share**.  **[1506251_0001213900-25-100847_ea026190901ex99-1_citius.htm:0]** **[1506251_0001213900-25-100847_ea026190901ex99-2_citius.htm:0]** 
- The common warrants have an exercise price of **$1.40 per share** and will expire five years from the initial exercise date.  **[1506251_0001213900-25-100847_ea026190901ex99-1_citius.htm:0]** **[1506251_0001213900-25-100847_ea026190901ex99-2_citius.htm:0]** **[1506251_0001213900-25-100847_ea0261909-8k_citius.htm:1]** **[1506251_0001213900-25-100847_ea026190901ex4-1_citius.htm:1]**  Pre-funded warrants are exercisable at **$0.0001 per share**.  **[1506251_0001213900-25-100847_ea0261909-8k_citius.htm:1]** 
- The company expects net proceeds of approximately **$5.5 million**, which will be used to support the **commercial launch of LYMPHIR™**, fund development initiatives for product candidates, and for general corporate purposes.  **[1506251_0001213900-25-100847_ea026190901ex99-1_citius.htm:0]** **[1506251_0001213900-25-100847_ea0261909-8k_citius.htm:1]** 
- H.C. Wainwright & Co. served as the exclusive placement agent, receiving a **7.0% cash fee** of the gross proceeds and warrants to purchase up to **278,146 shares** at an exercise price of **$1.8875 per share**.  **[1506251_0001213900-25-100847_ea0261909-8k_citius.htm:1]**

Citius Pharmaceuticals Announces Closing of $6.0 Million Registered Direct Offering

- Citius Pharmaceuticals Inc. (CTXR) announced the closing of a registered direct offering on **October 21, 2025**, generating approximately **$6.0 million** in gross proceeds.  **[1506251_20251021NE03473:0]** 
- The offering involved the sale of **3,973,510 shares** of common stock (or pre-funded warrants) and accompanying common warrants, priced at **$1.51 per share**.  **[1506251_20251021NE03473:0]** 
- The net proceeds are intended to support the commercial launch of **LYMPHIR™**, which received FDA approval in **August 2024**, as well as other product development initiatives and general corporate purposes.  **[1506251_20251021NE03473:0]**

Citius Pharmaceuticals Closes $6.0 Million Registered Direct Offering

- **Citius Pharmaceuticals** has entered into a definitive agreement for a registered direct offering of **3,973,510 shares** of its common stock (or pre-funded warrants) and accompanying common warrants.  **[1506251_20251021NE02907:0]** 
- The purchase price for each share (or pre-funded warrant) and accompanying common warrant is **$1.51**, with the common warrants having an exercise price of **$1.40 per share**.  **[1506251_20251021NE02907:0]** 
- The offering is expected to generate approximately **$6.0 million** in aggregate gross proceeds for the company.  **[1506251_20251021NE02907:0]** 
- The net proceeds are intended to support the commercial launch of **LYMPHIR™**, fund development initiatives for product candidates, and cover general corporate purposes.  **[1506251_20251021NE02907:0]** 
- The closing of the offering is anticipated on or about **October 21, 2025**.  **[1506251_20251021NE02907:0]**

Citius Pharmaceuticals (CTXR)